UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Use of recombinant zoster vaccine in immunocompromised adults aged ≥19 years: Recommendations of the Advisory Committee on Immunization Practices—United States, 2022

American journal of transplantation, 2022-03, Vol.22 (3), p.986-990

2022

Volltextzugriff (PDF)

Cost-effectiveness of dengue vaccination in Puerto Rico

PLoS neglected tropical diseases, 2021-07, Vol.15 (7), p.e0009606-e0009606

2021

Volltextzugriff (PDF)

Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults

Human vaccines & immunotherapeutics, 2022-11, Vol.18 (5), p.2060668-2060668

2022

Volltextzugriff (PDF)

Primary Care Use Among Commercially Insured Adolescents: Evidence From the 2018 Healthcare Effectiveness Data and Information Set

American journal of preventive medicine, 2021-03, Vol.60 (3), p.411-414

2021

Volltextzugriff (PDF)

A Review of Measles Outbreak Cost Estimates From the United States in the Postelimination Era (2004–2017): Estimates by Perspective and Cost Type

Clinical infectious diseases, 2020-09, Vol.71 (6), p.1568-1576

2020

Volltextzugriff (PDF)

Cost-Effectiveness Analysis of Routine Outreach and Catch-Up Campaign Strategies for Measles, Mumps, and Rubella Vaccination in Chuuk, Federated States of Micronesia

Public health reports (1974), 2024-06, p.333549241249672-333549241249672

2024

Volltextzugriff (PDF)

Cost-effectiveness of adult vaccinations: A systematic review

Vaccine, 2019-01, Vol.37 (2), p.226-234

2019

Volltextzugriff (PDF)

Hospitalizations and costs associated with hepatitis C and advanced liver disease continue to increase

Health Affairs, 2014-10, Vol.33 (10), p.1728-1735

2014

Volltextzugriff (PDF)

A review of health-related quality of life associated with pneumococcal disease: pooled estimates by age and type of disease

Journal of public health (Oxford, England), 2022-06, Vol.44 (2), p.e234-e240

2022

Volltextzugriff (PDF)

Cost‐effectiveness of hepatitis C treatment for patients in early stages of liver disease

Hepatology (Baltimore, Md.), 2015-06, Vol.61 (6), p.1860-1869

2015

Volltextzugriff (PDF)

Insurance reimbursements for recombinant zoster vaccine in the private sector

Vaccine, 2021-08, Vol.39 (36), p.5091-5094

2021

Volltextzugriff (PDF)

Estimating the Effectiveness of Health-Risk Communications with Propensity-Score Matching: Application to Arsenic Groundwater Contamination in Four US Locations

Journal of Environmental and Public Health, 2014-01, Vol.2014 (2014), p.1-9

2014

Volltextzugriff (PDF)

Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine use among the pediatric population of the United States

Vaccine, 2023-05, Vol.41 (18), p.2914-2921

2023

Volltextzugriff (PDF)

Evaluation of temperature stability among different types and grades of vaccine storage units: Data from continuous temperature monitoring devices

Vaccine, 2020-03, Vol.38 (14), p.3008-3014

2020

Volltextzugriff (PDF)

Provider time and costs to vaccinate adult patients: Impact of time counseling without vaccination

Vaccine, 2019-02, Vol.37 (6), p.792-797

2019

Volltextzugriff (PDF)

A review of the cost-effectiveness of adult influenza vaccination and other preventive services

Preventive medicine, 2019-09, Vol.126, p.105734-105734, Article 105734

2019

Volltextzugriff (PDF)

Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022

MMWR. Morbidity and mortality weekly report, 2022-01, Vol.71 (4), p.109-117

2022

Volltextzugriff (PDF)

Societal Costs of a Measles Outbreak

Pediatrics (Evanston), 2021-04, Vol.147 (4), p.1

2021

Volltextzugriff (PDF)

Cost-effectiveness of vaccinating adults aged 60 years and older against respiratory syncytial virus

Vaccine, 2024-10, Vol.42 (24), p.126294, Article 126294

2024

Volltextzugriff (PDF)

Review of the economic evidence presented to the United States Advisory Committee on Immunization Practices, 2012–2016

Vaccine, 2019-01, Vol.37 (1), p.7-10

2019

Volltextzugriff (PDF)

Cost-Effectiveness Analysis of Vaccination With Recombinant Zoster Vaccine Among Hematopoietic Cell Transplant Recipients and Persons With Other Immunocompromising Conditions Aged 19 to 49 Years

Value in health, 2023-02, Vol.26 (2), p.204-215

2023

Volltextzugriff (PDF)

Estimating the Costs and Income of Providing Vaccination to Adults and Children

Medical care, 2019-06, Vol.57 (6), p.410-416

2019

Volltextzugriff (PDF)

Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022

MMWR. Morbidity and mortality weekly report, 2022-01, Vol.71 (3), p.80-84

2022

Volltextzugriff (PDF)

Tetanus, diphtheria and acellular pertussis (Tdap) vaccine for prevention of pertussis among adults aged 19 years and older in the United States: A cost-effectiveness analysis

Preventive medicine, 2020-05, Vol.134, p.106066-106066, Article 106066

2020

Volltextzugriff (PDF)

Analysis of the profitability of adult vaccination in 13 private provider practices in the United States

Vaccine, 2019-09, Vol.37 (42), p.6180-6185

2019

Volltextzugriff (PDF)

1 – 25 von 70

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(57)
Mit Volltextzugriff
(62)

Publikationsform

Sprache

Englisch
(70)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(58)
Life Sciences & Biomedicine
(55)
Humans
(40)
Vaccines
(24)
Immunization
(23)
Adult
(20)
Public Health
(19)
Female
(17)
Public, Environmental & Occupational Health
(17)
Middle Aged
(16)
United States
(14)
United States - Epidemiology
(14)
Vaccination
(14)
Male
(13)
Costs
(12)
Immunology
(12)
Mortality
(11)
Aged
(10)
Medicine, Research & Experimental
(10)
Research & Experimental Medicine
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Use of recombinant zoster vaccine in immunocompromised adults aged ≥19 years: Recommendations of the Advisory Committee on Immunization Practices—United States, 2022

Cost-effectiveness of dengue vaccination in Puerto Rico

Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults

Primary Care Use Among Commercially Insured Adolescents: Evidence From the 2018 Healthcare Effectiveness Data and Information Set

A Review of Measles Outbreak Cost Estimates From the United States in the Postelimination Era (2004–2017): Estimates by Perspective and Cost Type

Cost-Effectiveness Analysis of Routine Outreach and Catch-Up Campaign Strategies for Measles, Mumps, and Rubella Vaccination in Chuuk, Federated States of Micronesia

Cost-effectiveness of adult vaccinations: A systematic review

Hospitalizations and costs associated with hepatitis C and advanced liver disease continue to increase

A review of health-related quality of life associated with pneumococcal disease: pooled estimates by age and type of disease

Cost‐effectiveness of hepatitis C treatment for patients in early stages of liver disease

Insurance reimbursements for recombinant zoster vaccine in the private sector

Estimating the Effectiveness of Health-Risk Communications with Propensity-Score Matching: Application to Arsenic Groundwater Contamination in Four US Locations

Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine use among the pediatric population of the United States

Evaluation of temperature stability among different types and grades of vaccine storage units: Data from continuous temperature monitoring devices

Provider time and costs to vaccinate adult patients: Impact of time counseling without vaccination

A review of the cost-effectiveness of adult influenza vaccination and other preventive services

Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022

Societal Costs of a Measles Outbreak

Cost-effectiveness of vaccinating adults aged 60 years and older against respiratory syncytial virus

Review of the economic evidence presented to the United States Advisory Committee on Immunization Practices, 2012–2016

Cost-Effectiveness Analysis of Vaccination With Recombinant Zoster Vaccine Among Hematopoietic Cell Transplant Recipients and Persons With Other Immunocompromising Conditions Aged 19 to 49 Years

Estimating the Costs and Income of Providing Vaccination to Adults and Children

Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022

Tetanus, diphtheria and acellular pertussis (Tdap) vaccine for prevention of pertussis among adults aged 19 years and older in the United States: A cost-effectiveness analysis

Analysis of the profitability of adult vaccination in 13 private provider practices in the United States

Suchergebnisse filtern